Back to News
Market Impact: 0.15
Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results
Source: Nasdaq
Healthcare & Biotech
On November 5, 2026, Eton Pharmaceuticals announced preliminary results from a randomized, double-blind, placebo-controlled pilot study of ET-700, an investigational extended-release zinc acetate formulation being developed for Wilson disease. The provided article text does not include the results or numerical findings, so their clinical or market implications cannot be assessed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
ETON0.00
More News
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Jefferies raises Inovio stock price target on regulatory win
- Truist raises Vericel stock price target on MACI growth momentum
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs
- IRTC Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into iRhythm Technologies, Inc. (IRTC)